Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma

被引：15

作者：

Kobayashi, Kazuo ^{[1
,2
]}

Iikura, Yusuke ^{[1
]}

Hiraide, Makoto ^{[3
]}

Yokokawa, Takashi ^{[1
]}

Aoyama, Takeshi ^{[1
]}

Shikibu, Sari ^{[1
]}

Hashimoto, Koki ^{[1
]}

Suzuki, Kenichi ^{[3
]}

Sato, Hitoshi ^{[2
]}

Sugiyama, Erika ^{[2
]}

Tajima, Masataka ^{[2
]}

Hama, Toshihiro ^{[1
]}

机构：

[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Pharm, Tokyo, Japan

[2] Showa Univ, Sch Pharm, Dept Pharmacol Toxicol & Therapeut, Div Pharmacokinet & Pharmacodynam, Tokyo, Japan

[3] Hoshi Univ, Div Appl Pharmaceut Educ & Res, Tokyo, Japan

来源：

IN VIVO | 2020年 / 34卷 / 05期

关键词：

Immune-related adverse events; nivolumab; overall survival; progression-free survival; metastatic renal cell carcinoma; CHECKPOINT INHIBITORS; CANCER PATIENTS; EFFICACY;

D O I：

10.21873/invivo.12083

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Background/Aim: Immune-related adverse events (irAEs) are associated with the efficacy of immune-checkpoint inhibitors in patients with melanoma and non-small cell lung cancer. We therefore evaluated the relationship between irAEs and nivolumab efficacy against metastatic renal cell carcinoma. Patients and Methods: The medical records of 53 consecutive patients were reviewed and analyzed. Results: Median overall survival was significantly better in patients who showed irAEs at any time compared to patients without irAEs (p=0.013). We identified irAEs in 24 of 53 patients (45.3%), including four patients (75%) with grade 3 events. Multivariate analysis also revealed that risk factors for the onset of irAEs were positively associated with a platelet-to-lymphocyte ratio <156 before nivolumab treatment (p=0.006). Conclusion: Development of irAEs was associated with survival outcomes of nivolumab treated patients with metastatic renal cell carcinoma.

引用

页码：2647 / 2652

页数：6

共 50 条

[11] Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis
Satoshi Washino
Suguru Shirotake
Hideki Takeshita
Masaharu Inoue
Yuji Miura
Yoji Hyodo
Makoto Kagawa
Keita Izumi
Masafumi Oyama
Satoru Kawakami
Kazutaka Saito
Yoh Matsuoka
Satsuki Taniuchi
Ayumi Shintani
Tomoaki Miyagawa
International Journal of Clinical Oncology, 2023, 28 : 1651 - 1658
[12] Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis
Washino, Satoshi
Shirotake, Suguru
Takeshita, Hideki
Inoue, Masaharu
Miura, Yuji
Hyodo, Yoji
Kagawa, Makoto
Izumi, Keita
Oyama, Masafumi
Kawakami, Satoru
Saito, Kazutaka
Matsuoka, Yoh
Taniuchi, Satsuki
Shintani, Ayumi
Miyagawa, Tomoaki
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (12) : 1651 - 1658
[13] Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies
Les, Inigo
Martinez, Mireia
Narro, Alicia
Perez, Ines
Sanchez, Cristina
Punti, Laura
Anaut, Pilar
Eguiluz, Saioa
Herrera, Alberto
Dominguez, Severina
ANNALS OF MEDICINE, 2021, 53 (01) : 762 - 769
[14] Association of Immune-Related Adverse Events with Pembrolizumab Efficacy in the Treatment of Advanced Urothelial Carcinoma
Kobayashi, Kazuo
Suzuki, Kenichi
Hiraide, Makoto
Aoyama, Takeshi
Yokokawa, Takashi
Shikibu, Sari
Hashimoto, Koki
Iikura, Yusuke
Sato, Hitoshi
Sugiyama, Erika
Tajima, Masataka
Hama, Toshihiro
ONCOLOGY, 2020, 98 (04) : 237 - 242
[15] Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study
Nukaya, Takuhisa
Takahara, Kiyoshi
Yoshizawa, Atsuhiko
Saruta, Masanobu
Yano, Yusuke
Ohno, Takaya
Uchimoto, Taizo
Fukuokaya, Wataru
Adachi, Takahiro
Yamazaki, Shogo
Tokushige, Satoshi
Nishimura, Kazuki
Tsujino, Takuya
Nakamori, Keita
Yamamoto, Shutaro
Iwatani, Kosuke
Urabe, Fumihiko
Mori, Keiichiro
Yanagisawa, Takafumi
Tsuduki, Shunsuke
Hirasawa, Yosuke
Hashimoto, Takeshi
Komura, Kazumasa
Inamoto, Teruo
Miki, Jun
Kimura, Takahiro
Ohno, Yoshio
Azuma, Haruhito
Shiroki, Ryoichi
CLINICAL GENITOURINARY CANCER, 2024, 22 (01) : 76 - 83
[16] Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer
Mouri, Atsuto
Kaira, Kyoichi
Yamaguchi, Ou
Shiono, Ayako
Miura, Yu
Hashimoto, Kosuke
Nishihara, Fuyumi
Murayama, Yoshitake
Kobayashi, Kunihiko
Kagamu, Hiroshi
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (04) : 873 - 880
[17] The prognostic impact of immune-related adverse events in metastatic renal cell carcinoma patients treated with nivolumab: a real-world multi-institutional retrospective study
Taigo Kato
Akira Nagahara
Norihiko Kawamura
Wataru Nakata
Tetsuji Soda
Kyosuke Matsuzaki
Koji Hatano
Atsunari Kawashima
Takeshi Ujike
Ryoichi Imamura
Kensaku Nishimura
Shingo Takada
Masao Tsujihata
Seiji Yamaguchi
Tetsuya Takao
Kazuo Nishimura
Norio Nonomura
Motohide Uemura
International Journal of Clinical Oncology, 2021, 26 : 954 - 961
[18] Clinical assessment of immune-related adverse events
Sosa, Aaron
Lopez Cadena, Esther
Simon Olive, Cristina
Karachaliou, Niki
Rosell, Rafael
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
[19] Clinical outcome in recurrent and/or metastatic head and neck cancer patients after discontinuation of nivolumab monotherapy due to immune-related adverse events
Yasumatsu, Ryuji
Matsuo, Mioko
Wakasaki, Takahiro
Masuda, Muneyuki
Takeuchi, Toranoshin
Manako, Tomomi
Jiromaru, Rina
Uchi, Ryutaro
Hashimoto, Kazuki
Nakagawa, Takashi
ACTA OTO-LARYNGOLOGICA, 2020, 140 (12) : 1043 - 1048
[20] Association between immune-related adverse events and the prognosis of patients with gastric cancer treated with nivolumab: a meta-analysis
Zhang, Ya-Jun
Tian, Qian-Yu
Wang, Cai-E.
FRONTIERS IN ONCOLOGY, 2024, 14

← 1 2 3 4 5 →